The AI-driven wearable sensor demonstrates high accuracy in reducing nighttime scratching for atopic dermatitis, improving ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

A recent study published in the Dermatology and Therapy journal confirmed the effectiveness and safety of upadacitinib, a ...

Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...